Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.

MLA

Voso, Maria-Teresa, et al. “Clonal Haematopoiesis as a Risk Factor for Therapy-Related Myeloid Neoplasms in Patients with Chronic Lymphocytic Leukaemia Treated with Chemo-(Immuno)Therapy.” British Journal of Haematology, vol. 198, no. 1, July 2022, pp. 103–13. EBSCOhost, https://doi.org/10.1111/bjh.18129.

APA

Voso, M.-T., Pandzic, T., Falconi, G., Denčić-Fekete, M., De Bellis, E., Scarfo, L., Ljungström, V., Iskas, M., Del Poeta, G., Ranghetti, P., Laidou, S., Cristiano, A., Plevova, K., Imbergamo, S., Engvall, M., Zucchetto, A., Salvetti, C., Mauro, F. R., Stavroyianni, N., … Baliakas, P. (2022). Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. British Journal of Haematology, 198(1), 103–113. https://doi.org/10.1111/bjh.18129

Chicago

Voso, Maria-Teresa, Tatjana Pandzic, Giulia Falconi, Marija Denčić-Fekete, Eleonora De Bellis, Lydia Scarfo, Viktor Ljungström, et al. 2022. “Clonal Haematopoiesis as a Risk Factor for Therapy-Related Myeloid Neoplasms in Patients with Chronic Lymphocytic Leukaemia Treated with Chemo-(Immuno)Therapy.” British Journal of Haematology 198 (1): 103–13. doi:10.1111/bjh.18129.